Akt and CHIP Coregulate Tau Degradation Through Coordinated Interactions
Overview
Authors
Affiliations
A hallmark of the pathology of Alzheimer's disease is the accumulation of the microtubule-associated protein tau into fibrillar aggregates. Recent studies suggest that they accumulate because cytosolic chaperones fail to clear abnormally phosphorylated tau, preserving a pool of toxic tau intermediates within the neuron. We describe a mechanism for tau clearance involving a major cellular kinase, Akt. During stress, Akt is ubiquitinated and degraded by the tau ubiquitin ligase CHIP, and this largely depends on the Hsp90 complex. Akt also prevents CHIP-induced tau ubiquitination and its subsequent degradation, either by regulating the Hsp90/CHIP complex directly or by competing as a client protein with tau for binding. Akt levels tightly regulate the expression of CHIP, such that, as Akt levels are suppressed, CHIP levels also decrease, suggesting a potential stress response feedback mechanism between ligase and kinase activity. We also show that Akt and the microtubule affinity-regulating kinase 2 (PAR1/MARK2), a known tau kinase, interact directly. Akt enhances the activity of PAR1 to promote tau hyperphosphorylation at S262/S356, a tau species that is not recognized by the CHIP/Hsp90 complex. Moreover, Akt1 knockout mice have reduced levels of tau phosphorylated at PAR1/MARK2 consensus sites. Hence, Akt serves as a major regulator of tau biology by manipulating both tau kinases and protein quality control, providing a link to several common pathways that have demonstrated dysfunction in Alzheimer's disease.
Sanajou S, Yirun A, Demirel G, Erkekoglu P, Sahin G, Baydar T J Appl Toxicol. 2024; 45(2):245-255.
PMID: 39275926 PMC: 11738538. DOI: 10.1002/jat.4695.
Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP.
Nadel C, Pokhrel S, Wucherer K, Oehler A, Thwin A, Basu K Nat Commun. 2024; 15(1):7972.
PMID: 39266525 PMC: 11393453. DOI: 10.1038/s41467-024-52075-1.
Chaperones-A New Class of Potential Therapeutic Targets in Alzheimer's Disease.
Batko J, Antosz K, Miskow W, Pszczolowska M, Walczak K, Leszek J Int J Mol Sci. 2024; 25(6).
PMID: 38542375 PMC: 10970155. DOI: 10.3390/ijms25063401.
Role of MARK2 in the nervous system and cancer.
Lei Y, Zhang R, Cai F Cancer Gene Ther. 2024; 31(4):497-506.
PMID: 38302729 DOI: 10.1038/s41417-024-00737-z.
Kumar M, Quittot N, Dujardin S, Schlaffner C, Viode A, Wiedmer A Brain. 2024; 147(2):637-648.
PMID: 38236720 PMC: 10834235. DOI: 10.1093/brain/awad378.